First in Human Study to Assess Safety of VIS649 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

August 10, 2019

Study Completion Date

August 10, 2019

Conditions

Immunoglobulin A NephropathyIgAN - IgA NephropathyIgA Nephropathy

Interventions

BIOLOGICAL

VIS649

Single IV dose of study product on Day 1 of study

BIOLOGICAL

Placebo

Singe IV dose of placebo administered via IV on Day 1 of study

Trial Locations (1)

California Clinical Trials Medical Group, Glendale

All Listed Sponsors

lead

Visterra, Inc.

INDUSTRY

NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects | Biotech Hunter | Biotech Hunter